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Abstract
Background: Before antiretroviral therapy (ART) became widely available in sub-Saharan Africa, several studies
demonstrated that daily trimethoprim-sulfamethoxazole (TS) prophylaxis reduced morbidity and mortality among
HIV-infected adults. As a result, the World Health Organization (WHO) recommended administering TS prophylaxis
to this group. However, the applicability of the results to individuals taking ART and living in sub-Saharan Africa has
not been definitively evaluated. This study aims to determine if TS prophylaxis benefits HIV-infected Malawian
adults after a good response to ART. If TS prophylaxis does indeed show benefit, it is important to determine if this
is due to its antibacterial and/or antimalarial properties.
Methods/design: A randomized, controlled, open-label, phase III trial of continued standard of care prophylaxis
with daily trimethoprim-sulfamethoxazole (TS) compared to discontinuation of standard of care TS prophylaxis and
starting weekly chloroquine (CQ) prophylaxis or discontinuation of standard of care TS prophylaxis. The study will
randomize 1400–1500 HIV-infected adults (equally divided over the three study arms) with a nondetectable viral
load and a CD4 count of 250/mm3 or more from antiretroviral therapy clinics in Blantyre and Zomba. The expected
rate of primary endpoint events of death and WHO stage 3 and 4 events is 6.8 per 100 person-years of follow-up in
all participants. Assuming the number of events follows a Poisson distribution and average participant follow-up
after 10 % loss to follow-up is 41.6 months, the study will have approximately 85 % power to rule out a reduction
of 35 % or more in primary endpoint events in the TS or CQ arms compared to discontinuation of TS
prophylaxis—i.e., to show that discontinuation of TS prophylaxis is noninferior to either TS or CQ, with a
noninferiority margin of 35 %. Ethical and regulatory approvals were obtained from the University of Malawi
College of Medicine Research Ethics Committee; the Malawi Pharmacy, Medicines and Poisons Board; and the
University of Maryland Baltimore Institutional Review Board.
(Continued on next page)
* Correspondence: mlaurens@medicine.umaryland.edu
1Division of Malaria Research, Institute for Global Health, University of
Maryland School of Medicine, 480 W Baltimore St, Room 480, Baltimore, MD
21218, USA
Full list of author information is available at the end of the article
© 2016 Laurens et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Laurens et al. Trials  (2016) 17:322 
DOI 10.1186/s13063-016-1392-3
(Continued from previous page)
Discussion: The study began recruitment activities at the Ndirande site in November 2012. The sponsor agreed to
extend and expand the study in early 2015, and a second site, Zomba, was added for recruitment and follow-up in
mid-2015.
Trial registration: ClinicalTrials.gov Identifier: NCT01650558 (registered on 6 July 2012).
Protocol version: Letter of amendment #1 to the DAIDS-ES 10822 TSCQ Malawi Protocol, Version 4.0, 16
December 2014.
Keywords: HIV infection, Trimethoprim-sulfamethoxazole, Chloroquine, Immunosuppression, Longitudinal studies,
Malaria, Plasmodium falciparum, Parasitemia, Adult, Antiretroviral therapy, Malawi, Africa
Background and rationale
Background
Several studies have demonstrated that daily trimethoprim-
sulfamethoxazole (TS) prophylaxis reduces morbidity and
mortality among HIV-infected adults in sub-Saharan Africa
[1–4]. As a result of these studies the World Health
Organization (WHO) recommended administering TS
prophylaxis to this group. However, these studies were
completed prior to the widespread availability of antiretro-
viral therapy (ART), and the applicability of the results to
individuals taking ART has not been definitively evaluated.
A critical question remains about the need for, and duration
of, TS prophylaxis and its public health impact: Is there a
benefit to TS prophylaxis after patients have initiated and
responded to ART?
In North America and Europe, TS prophylaxis prevents
Pneumocystis jirovecii pneumonia (PCP) and toxoplasmosis,
and is discontinued after the CD4 cell count reaches 200/
mm3. However, a recent multicenter study demonstrated
that even with a CD4 cell count of 100–200/mm3, there is
minimal benefit of TS prophylaxis if the patient is taking
ART and the viral load is undetectable [5]. The risk of op-
portunistic infections, at least those infections common in
Western countries, is very low once ART is successful, even
with low CD4 cell counts.
In contrast, studies in Africa have not determined
whether there is a point when TS prophylaxis no longer
confers an advantage with respect to survival or morbid-
ity. There is consistent evidence to support the use of a
CD4 cell count of more than 200 cells/mm3 as a thresh-
old above which TS prophylaxis survival benefit is absent
among individuals receiving ART [3, 6]. However, the
broad benefit of TS to prevent bacteremia, pneumonia,
enteritis and malaria has not been consistently docu-
mented in adults taking ART who live in sub-Saharan
Africa. In the Development of Antiretroviral Therapy in
Africa (DART) study, the only clear disease-specific
benefit of TS was in the prevention of malaria; TS did
not prevent WHO clinical stage 4 illnesses [6]. A clinical
trial to assess the benefit of TS prophylaxis in a popula-
tion of Ugandan adults taking ART was stopped early
because the group taking TS prophylaxis had fewer non-
severe clinical events, such as uncomplicated malaria
and diarrheal illnesses, than the control group [7]. A
similar study of TS discontinuation was recently con-
ducted in Ugandan adults to assess the TS prophylaxis
benefit with respect to hematological adverse events [8].
Although the main outcome is not yet published, inves-
tigators did report a decrease in malaria among partici-
pants taking TS therapy [9]. Another study randomized
Kenyan adults taking ART to continue or stop TS
prophylaxis, and found that after 1 year of follow-up, TS
did not change morbidity and mortality with the excep-
tion of fewer malaria cases in the TS arm, and no
changes in CD4 count or ART failure were noted over
time [10]. Malaria prevention is potentially important, as
it is associated with transient increases in HIV viral load
[11]. However, it is not known if these increases are as-
sociated with loss of virologic suppression leading to
HIV disease progression.
At the study sites, daily TS prophylaxis is currently
used by all persons taking ART [12], and is recom-
mended to be continued for life in the absence of severe
side effects as there are no randomized, controlled trials
to determine whether or when to stop TS in persons
taking ART.
Rationale
The role of TS prophylaxis in the context of long-term
ART is an important issue now facing ART programs
in Africa. Currently, the updated WHO recommenda-
tion calls for TS prophylaxis in those with a CD4
count of 350 cells/mm3 or less in areas where bacterial
infection and malaria are prevalent [13]. However, this
recommendation is based on expert opinion and not
on randomized, controlled trials. Some data from
resource-limited settings suggest that it may be safe to
discontinue TS among those with immune recovery
and a CD4 count above 200 cells/mm3 in response to
ART [14, 15]. To date, no randomized clinical trials
have assessed the safety and timing of discontinuation
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of TS prophylaxis following immune recovery in re-
sponse to ART in resource-limited settings [16].
The main study hypotheses are that TS confers a long-
term benefit on survival and disease control and that the
benefit is largely attributable to the prevention of malaria.
The study design takes advantage of the unique opportun-
ity in Malawi, where malaria is uniformly susceptible to
CQ [17, 18]. In addition to a TS continuation arm and a
TS discontinuation control arm, a third arm receives only
CQ prophylaxis. Individuals who receive CQ will be receiv-
ing extremely effective malaria prevention but will not be
protected against bacterial infection. Thus, one study arm
prevents both bacterial and parasitic infection, a second
arm prevents just malaria and the third arm will not re-
ceive prophylaxis.
This study will inform HIV policy throughout Africa.
TS prophylaxis at approximately one billion doses/
year could potentially be removed from the ART regi-
men or, if it is beneficial, its use could be more
broadly reinforced as a method of saving lives and
prolonging the efficacy of the available ART. A control
arm that discontinues TS prophylaxis after good clin-
ical and virologic response to ART is included in the
study because of clinical equipoise regarding the bene-
fit of prophylaxis in this population. A randomized
clinical trial is needed to definitively inform health
policy in Malawi and other sub-Saharan African coun-
tries that currently continue TS prophylaxis after suc-
cessful ART therapy [16].
Overview of the trial
A randomized, controlled, open-label, phase III trial of
continued standard of care prophylaxis with daily TS
compared to (1) discontinuation of standard of care TS
prophylaxis and starting weekly chloroquine (CQ)
prophylaxis, or (2) discontinuation of standard of care
TS prophylaxis.
Study aim: to assess the need for antimicrobial
prophylaxis in HIV-infected adults taking ART in sub-
Saharan Africa.
Intervention: continue daily TS, stop daily TS, or stop
daily TS and start weekly CQ.
Randomization: 1:1:1 to each study intervention, using
block randomization and stratified by site.
Primary endpoint: the occurrence of a severe event
(WHO stage 3 or 4 event or death, see Table 1).
Antiretroviral therapy: continued in all participants as
per Malawi Ministry of Health guidelines.
Secondary endpoints: undetectable (less than 400 cop-
ies/mL) HIV viral load and CD4 cell count assessed
every 24 weeks, incidence of WHO HIV stage 2-, 3- or
4-defining illnesses or death, the occurrence of any sus-
pected and laboratory-confirmed infection with bacteria
or malaria, the occurrence of grade 3 or above adverse
events (AEs) and rate of discontinuation of TS or CQ
prophylaxis.
Sample size: 1400–1500 participants (approximately
1000–1100 from Blantyre and 400–500 from Zomba).
Study sites: Blantyre and Zomba, Malawi.
Study sponsor: US National Institutes of Health, National
Institute of Allergy and Infectious Diseases, Division of
Acquired Immunodeficiency Syndrome.
Study duration (recruitment and follow-up): 5.5 years.
Study objectives
Primary objective
To determine if prophylaxis with TS or CQ, compared
to no prophylaxis, is associated with improved morbidity
and mortality among adults receiving ART beyond
6 months.
Secondary objectives
The secondary objectives are as follows: (1) to assess the
effect of prophylaxis with TS or CQ on the virologic, im-
munologic and clinical response to ART, (2) to assess
the efficacy of TS in preventing infection with bacteria
or malaria, and (3) to assess the safety and tolerability of
TS and CQ prophylaxis.
Exploratory objectives
Exploratory objectives include the following: (1) to
evaluate the effect of TS and CQ prophylaxis on the in-
cidence of drug-resistant organisms, and (2) to evaluate
the efficacy of antimalarial treatment.
Primary endpoint
The occurrence of a severe event (WHO stage 3 or 4
event or death).
Secondary endpoints
Virologic: undetectable (less than 400 copies/mL) HIV viral
load assessed every 24 weeks
Intercurrent infection may increase HIV viral load replica-
tion and could lead to expansion of ART-resistant HIV and
loss of viral suppression. We will compare the ability of
prophylactic TS and CQ to prevent loss of viral suppression
compared to no prophylaxis.
Immunologic: CD4 cell count assessed every 24 weeks
During intercurrent illness, the CD4 count may decline
and lead to increased susceptibility to opportunistic infec-
tions. Prevention of infection with TS or CQ prophylaxis
could avoid this decline and worsening of immunosup-
pression. We will analyze the ability of prophylactic TS
and CQ to prevent CD4 cell count decline compared to
no prophylaxis.
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Clinical: incidence of WHO HIV stage 2-, 3- or 4-defining ill-
nesses or death
In addition to the severe event outcomes listed in the
primary endpoint section, the capacity of TS or CQ
prophylaxis to prevent WHO stage 2 illnesses will be evalu-
ated to permit assessment of a broader range of disease and
illness prevention.
The occurrence of all suspected and also laboratory-
confirmed infection with bacteria or malaria
TS prophylaxis is expected to prevent both malaria and
bacterial infections. Other studies document TS prophylac-
tic efficacy in areas of underlying high rates of bacter-
ial and malarial resistance [3, 4, 19], and the current
study will evaluate the effect of TS in this popula-
tion. Due to the return of CQ-sensitive Plasmodium
falciparum to Malawi, CQ is expected to be highly
efficacious at preventing malaria, but not opportunistic
infections.
The occurrence of grade 3 or above adverse events and
rate of discontinuation of TS or CQ prophylaxis
As a relatively long-term prophylactic regimen, both
daily TS and weekly CQ may cause adverse effects that
should be accounted for in the risk-benefit analysis of
prophylaxis. Evaluation of the incidence of severe and
life-threatening events and deaths in each study arm al-
lows for comparison of a baseline event rate to events in
the TS and CQ prophylaxis groups. The incidence of
events that lead to discontinuation of prophylaxis is also
important when policymakers evaluate potential first-
line prophylactic regimens and the need for second-line
therapies.
Exploratory endpoints
The occurrence of all bacterial infections with antibiotic-
resistant organisms
TS prophylaxis has shown benefit in areas where TS re-
sistance is documented. To confirm this finding, we aim
to document the efficacy of TS in preventing TS-resistant
bacterial infections in our study setting.
Table 1 Revised World Health Organization clinical staging for
HIV/AIDS for adults and adolescents with confirmed HIV
infection
Clinical stage 2
• Moderate unexplained weight loss (5–10 % of presumed or
measured body weight)
• Recurrent respiratory tract infections (sinusitis, tonsillitis, otitis media
and pharyngitis)
• Herpes zoster
• Angular cheilitis
• Recurrent oral ulceration
• Papular pruritic eruptions
• Seborrhoeic dermatitis
• Fungal nail infections
Clinical stage 3
• Unexplained severe weight loss (>10 % of presumed or measured
body weight)
• Unexplained chronic diarrhoea for longer than 1 month
• Unexplained persistent fever (above 37.5 °C intermittent or constant,
for longer than 1 month)
• Persistent oral candidiasis
• Oral hairy leukoplakia
• Pulmonary tuberculosis
• Severe bacterial infections (e.g., pneumonia, empyema, pyomyositis,
bone or joint infection, bacteremia, severe pelvic inflammatory
disease)
• Acute necrotizing ulcerative stomatitis, gingivitis or periodontitis
• Unexplained anemia (<8 g/dl), neutropenia (<500/mm3) and/or
chronic thrombocytopenia (<50,000/mm3)
Clinical stage 4
• HIV wasting syndrome
• Pneumocystis jirovecii pneumonia
• Recurrent severe bacterial pneumonia
• Chronic herpes simplex infection (orolabial, genital or anorectal of
more than 1 month’s duration or visceral at any site)
• Oesophageal candidiasis (or candidiasis of the trachea, bronchi or
lungs)
• Extrapulmonary tuberculosis
• Kaposi’s sarcoma
• Cytomegalovirus infection (retinitis or infection of other organs,
excluding liver, spleen or lymph nodes)
• Central nervous system toxoplasmosis
• HIV encephalopathy
• Extrapulmonary cryptococcosis including meningitis
• Disseminated nontuberculous mycobacterial infection
• Progressive multifocal leukoencephalopathy (PML)
• Candida of trachea, bronchi or lungs
• Chronic cryptosporidiosis
• Chronic isosporiasis
• Disseminated mycosis (histoplasmosis, coccidiomycosis)
Table 1 Revised World Health Organization clinical staging for
HIV/AIDS for adults and adolescents with confirmed HIV
infection (Continued)
• Recurrent septicemia (including nontyphoidal Salmonella)
• Lymphoma (cerebral or B-cell non-Hodgkin)
• Invasive cervical carcinoma
• Atypical disseminated leishmaniasis
• Symptomatic HIV-associated nephropathy or symptomatic HIV-
associated cardiomyopathy
Laurens et al. Trials  (2016) 17:322 Page 4 of 18
Clinical and parasitological response to antimalarial
therapy in cases of uncomplicated malaria
ART may change the pharmacokinetic profile of artemi-
sinin combination therapies (ACT) used for first-line
treatment of uncomplicated malaria in Malawi. Docu-
menting the clinical and parasitological response to
these antimalarials serves to evaluate their effectiveness.
Reduced efficacy of ACT would signal the need for alter-
nate antimalarial therapies in this population.
Methods/design
This randomized, controlled, open-label, phase III trial
will compare standard of care TS prophylaxis and CQ
prophylaxis to no prophylaxis. Adults who have been re-
ceiving ART for at least 6 months with good clinical re-
sponse, and who fulfill the eligibility criteria, will be
randomized in a 1:1:1 ratio to one of three arms: (1) to
continue standard of care TS prophylaxis, (2) to discon-
tinue standard of care TS prophylaxis and begin weekly
CQ prophylaxis, or (3) to discontinue standard of care
TS prophylaxis. Participants will be asked to return to
the research clinic every 4 weeks for the first 24 weeks
then every 12 weeks thereafter, and any time they are ill.
Participation will last for 32–66 months. Participants
who develop a WHO clinical stage 3 or 4 illness, experi-
ence a sustained decline in their CD4 count below 200
cells/mm3, or who experience ART failure will be placed
on standard of care TS prophylaxis (Fig. 1).
The study population is comprised of 1400–1500
Malawian adults living with HIV in or near Blantyre or
Zomba, Malawi. Participants must be taking ART for at
least 6 months with good clinical response, and have an
undetectable HIV viral load and a CD4 count of 250/
mm3 or more. Major exclusion criteria include severe
acute illness, chronic treatment or secondary prophylaxis
with any drug with antimalarial or antibacterial activity,
a history of hypersensitivity to antifolate drugs or CQ,
anemia, thrombocytopenia, neutropenia, liver or kidney
failure, and pregnancy. Ethical and regulatory approvals
were obtained from the University of Malawi College of
Medicine Research Ethics Committee; the Malawi Phar-
macy, Medicines and Poisons Board; and the University
of Maryland Baltimore Institutional Review Board.
TS prophylaxis dose
Trimethoprim-sulfamethoxazole (TS) will be provided in
tablet form containing 80 mg trimethoprim and 400 mg
sulfamethoxazole or 160 mg trimethoprim and 800 mg
sulfamethoxazole, manufactured by pharmaceutical
companies approved by the US Food and Drug Adminis-
tration (FDA) or PEPFAR for TS manufacturing. The
dose for prophylaxis is either two tablets (each contain-
ing 80 mg trimethoprim and 400 mg sulfamethoxazole)
or one tablet (each containing 160 mg trimethoprim and
800 mg sulfamethoxazole) to be taken every day by
mouth.
CQ prophylaxis dose
Chloroquine (CQ) will be provided in 500-mg tablet
form containing 300 mg chloroquine base, or in 200–
250-mg tablet form containing 155 mg chloroquine base,
manufactured by pharmaceutical companies approved
by the US FDA, Global Fund, or PEPFAR for CQ manu-
facturing. The dose for prophylaxis is one or two tablets
to be taken every 7 days by mouth, for a total weekly
dose of 300–310 mg chloroquine base per week.
Study population
HIV-infected adults enrolled in ART clinics may enroll in
the study, provided that they have been taking ART for at
least 6 months, complete the informed consent process and
fulfill all the inclusion and exclusion criteria.
Study location
The study recruits participants from Blantyre and
Zomba, Malawi.
Fig. 1 Trial flow diagram
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Inclusion criteria
 Age 18 years or older
 Documented HIV-1 infection
 Initiation of ART through a government-sponsored
ART program at least 6 months previous
 Undetectable HIV viral load (less than 400 copies/mL)
 CD4 count 250/mm3 or more
 TS prophylaxis prescribed for at least the previous
2 months
 Intention to remain in the study area until the end
of the study period
 Informed consent from participant
 Female study volunteers of reproductive potential
must have a negative urine pregnancy test
performed within 20 days before randomization
 Female study volunteers of reproductive potential
who participate in sexual activity that could lead to
pregnancy must use contraception (male or female
condoms, diaphragm or cervical cap with
spermicide, intrauterine device, or hormone-based
contraceptive) while receiving their assigned study
drug and for 1 month after stopping the medications
Exclusion criteria
 Severe acute illness (defined as requiring
hospitalization at the time of screening or other
conditions such as laboratory abnormalities as
determined by the investigators)
 Chronic treatment (requiring therapy for more than
14 days) or secondary prophylaxis (for
toxoplasmosis, pneumocystis pneumonia, or
tuberculosis for example) with any drug with
antimalarial or antibacterial activity
 History of hypersensitivity to antifolate drugs or CQ
 Laboratory exclusion criteria
 Hemoglobin below 8.0 gm/dL
 Platelet count below 50,000/mm3
 Absolute granulocyte count below 500/mm3
 Serum alanine aminotransferase (ALT)
concentration above 210 U/L for men, and above
160 U/L for women
 Serum creatinine concentration above 3.3 mg/dl
(291.7 μmol/L) for men, and above 2.7 mg/dl
(238.7 μmol/L) for women
 History of visual field or retinal changes
 History of preexisting auditory damage
 History of porphyria
 History of psoriasis
 History of liver disease
 History of seizure disorder
 History of glucose-6-phosphate dehydrogenase
(G6PD) deficiency
 History of electrocardiogram (ECG) or cardiac
conduction abnormality, or cardiomyopathy
 History of myopathy
Study procedures (Table 2)
Recruitment
Individuals enrolled in ART clinics at Ndirande and
Zomba are eligible after 6 months of taking ART. The
ART clinic staff will inform patients in the ART program
about the possibility of enrolling in this study. No study-
related evaluations are undertaken before obtaining in-
formed consent. The study staff then ask the participant
about their plans to remain in the area and their willing-
ness to attend the research clinic for all scheduled and
unscheduled follow-up. Potentially eligible participants
are then requested to read the informed consent in ei-
ther English or Chichewa. The informed consent is read
and explained verbally in Chichewa to those who are un-
able to read. This verbal explanation is attended by a
witness who will also sign the consent form. After read-
ing or listening, the potential participant is asked to sign
the informed consent form. For those who cannot write,
a thumbprint is placed on the form, with the signature
and date of a witness. The document also allows the par-
ticipant to indicate how to handle specimens that remain
after the study procedures have been completed. Any
use of study samples that is outside the scope of the ob-
jectives of this protocol will be submitted for prior re-
view and approval by the appropriate Institutional
Review Board (IRB). After informed consent is obtained,
participants are given a signed copy of the informed
consent document and assigned a screening identifica-
tion number.
Screening
After informed consent is obtained, a numbered case rec-
ord folder is created for potential participants, including
demographic information, previous medication exposure,
ART history, allergy history and physical examination
documentation. The participant is also sent to the labora-
tory for venipuncture to collect 10–12 mL of blood to test
for the following:
 Complete blood count (CBC)
 Alanine aminotransferase (ALT) concentration
 Creatinine concentration
 CD4 count
 HIV viral load
Women of reproductive potential undergo urine preg-
nancy testing. All potential participants are given a
follow-up appointment to find out if the laboratory re-
sults are within the eligible range. Screening evaluations
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to determine eligibility are completed within 20 days of
study entry unless otherwise specified.
Randomization
Participants meeting all eligibility requirements are ran-
domized to one of the three study arms in a 1:1:1 ratio in
real time via an Internet data entry system that meets FDA
requirements for electronic records and signatures (21 CFR
part 11-compliant). A backup hard copy randomization
scheme devised by the study statistician is used in
case of Internet system failure. The study statistician
has no contact with participants or the study staff
who care for the participants. Data entry staff onsite
record the study arm assignment for the enrolled par-
ticipant. The participant then surrenders their current
stock of TS and receives a supply of the study drug,
if appropriate.
Blinding
Treatment arms are not masked as each has a different
regimen (TS is once daily while CQ is once weekly), and
because of the concern that a complicated placebo regi-
men may interfere with adherence to ART. This ap-
proach facilitates assessment of the effect of each
prophylaxis regimen on treatment adherence. Laboratory
technicians and the independent committee reviewing
potential WHO stage 3 and 4 events are blinded to par-
ticipant treatment assignment, whereas clinical staff are
not.
Enrollment
After randomization, baseline measurements of visual
acuity using Snellen vision testing, and WHO perform-
ance score (Table 3) and bednet use (Table 4) are
assessed and recorded. A dried blood spot specimen is
obtained. The participant is then escorted to the study
pharmacy. For those randomized to receive TS or CQ, a
supply of the study drug will be given to each participant
with instructions for how to take the medication. Partici-
pants will be asked to provide detailed directions to their
home and of their contact cell phone number, if avail-
able, to facilitate active follow-up.
Follow-up
Follow-up visits may be one of three types: routine visit,
unscheduled visit, or antimalarial efficacy follow-up.
Routine visits occur every 4–12 weeks (every 4 weeks
for the first 24 weeks, then every 12 weeks thereafter). Ini-
tially, to ensure participant compliance with the study
schedule and study drug regimen (if assigned to TS or
Table 2 Trial flow chart
Screening Enrollment Every 4 weeks for
1st 24 weeks, then
every 12 weeks
Additional
evaluations
every 24 weeks
Final study visit,
time of
termination
Premature
discontinuation of
study treatment
Unscheduled
Visits
Informed consent √
Review of past medical history √
Review of current complaints √ √ √ √ √
Medication history √ √ √ √
Bednet use √ √ √ √
WHO performance scale √ √ √ √
Complete blood count, alanine
aminotransferase, creatinine
√ √ √ √
Urine pregnancy test √ √a √a
CD4 count √ √ √ √
HIV viral load √ √ √ √
Filter paper sample √ √ √ √
Physical examination √ √ (limited) √ (limited) √ √ √ √
Visual acuity assessment √ √ √ √
Provision of medication √ √
Pill count and adherence interview √ √ √
aUrine pregnancy testing will be performed at all study visits only where pregnancy is suspected
Table 3 World Health Organization performance score
World Health Organization
performance score
Definition
1 Asymptomatic, normal activity
2 Symptomatic, normal activity
3 Bedridden <50 % of the day during
the last month
4 Bedridden ≥50 % of the day during
the last month
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CQ), participants will be followed every 4 weeks for the
first 24 weeks. Thereafter, participants will be followed
every 12 weeks, as is the standard of care for ART clinics
in Malawi. The encounter will include an interval history,
regimen adherence questionnaire (Table 5) and pill
counts, questions about off-study drug use and bednet use
(Table 4) and a physical examination. In addition, study
clinicians will record and/or update any AEs. Dried blood
spot samples are obtained, and women of reproductive
potential whose last menstrual period was more than
4 weeks prior to this, or whose clinical evaluation suggests
pregnancy, will undergo urine pregnancy testing. At rou-
tine visits every 24 weeks and the final study visit, approxi-
mately 10–12 mL of blood are drawn for determination of
CD4 count, HIV viral load, CBC, and ALT and creatinine
concentrations; visual acuity is assessed and the WHO
performance score (Table 3) is recorded. When partici-
pants are followed every 12 weeks, the study team contacts
them via cell phone (if number is provided) every 4–6
weeks to ask about their health and to request that they
come to the clinic for any current health problems.
During unscheduled visits, participants are evaluated ac-
cording to standard procedures for the evaluation and
treatment of illness as defined by the Ministry of Health. Ill-
nesses and other medical issues are recorded as AEs in the
participant records, and seriousness, severity, relationship
to study product and expectedness are recorded (Table 6).
If an unexpected adverse drug experience is observed that
is definitely or probably related to TS or CQ, it will be re-
ported to the US FDA using the MedWatch safety informa-
tion and adverse reporting system via the online system at
www.fda.gov/MedWatch/report.htm. Diagnoses of illnesses
experienced by participants will be documented based
on updated criteria for diagnoses established by the
ACTG group (http://www.hptn.org/web%20documents/
HPTN052/Appendix60V1.123Feb2007.pdf) when feasible
in this setting. If bacteremia or meningitis is suspected, a
specimen is collected for culture and isolated pathogens
undergo drug susceptibility testing. Any signs or symptoms
of malaria will prompt the collection of a malaria smear.
Participants who are diagnosed with malaria receive therapy
according to Malawi national policy.
Participants who are diagnosed with uncomplicated
clinical malaria are enrolled in a 28-day antimalarial effi-
cacy study with follow-up on days 1, 2, 3, 7, 14, 21 and 28.
On these days, finger-prick specimens for malaria smears
and dried blood spot collection are obtained (Table 7).
Standard definitions of adequate parasitological and clin-
ical response to antimalarial therapy will be used based on
current WHO guidelines (http://whqlibdoc.who.int/publi-
cations/2009/9789241597531_eng.pdf). Participants who
have clinical treatment failure will be administered rescue
therapy according to Malawi national policy. Cases of se-
vere malaria are referred to the hospital.
Antiretroviral therapy
Outpatient clinical care of study participants, including
ART management, is assumed by the study team at en-
rollment. The study pharmacist dispenses ART from the
government supply to participants at scheduled follow-
up visits. The study team provides adherence counseling
to participants when missed doses are noted or when
ART failure is suspected. Physicians specializing in HIV
care hold weekly hours at the research clinic to manage
complicated ART questions and HIV care.
Concomitant medications
At each visit, information on other medications and sup-
plements will be documented in the participant case rec-
ord forms, including indication, dose, frequency, and
start and stop dates.
Toxicity management
For TS, related AEs are managed according to treatment
guidelines based on the WHO grading scale for toxicity
in adults and adolescents (http://www.who.int/hiv/pub/
guidelines/ctxguidelines.pdf ). Other AEs associated with
the study drug will be managed by the study team.
For CQ, participants who experience a worsening in
visual acuity (defined as a change in two levels or more
Table 5 Regimen adherence questionnaire
1. How often do you feel that you have difficulty taking your HIV
medications on time? By “on time” we mean no more than 2 hours
before or 2 hours after the time your doctor told you to take it.
All of the time
Most of the time
Rarely
Never
2. On average, how many days per week would you say that you missed
at least one dose of your HIV medications?
Every day
4 to 6 days/week
2 or 3 days/week
Once a week
Less than once a week
Never
3. When was the last time you missed at least one dose of your HIV
medications?
Within the past week
1 to 2 weeks ago
3 to 4 weeks ago
Between 1 and 3 months ago
More than 3 months ago
Never
Table 4 Bednet use data collection
Uses bednet Yes No
If yes:
Used most nights in last 4 weeks? Yes No
Used last night? Yes No
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using Snellen testing) or other visual complaints, muscle
weakness, or hearing defects while taking CQ will dis-
continue CQ prophylaxis and will be referred to the
ophthalmology or appropriate clinic for further evalu-
ation and treatment. They will be placed on TS prophy-
laxis after CQ is discontinued.
Discontinuation of study treatment assignment
If a participant is diagnosed with a WHO clinical stage 3 or
4 illness during the course of the study, or if their CD4
count is confirmed at below 200 cells/mm3, or they experi-
ence ART failure, they are given daily TS prophylaxis and
followed according to the study protocol. If they had been
assigned to CQ prophylaxis, the CQ will be stopped. They
will not be withdrawn from the study for this reason.
If a participant becomes pregnant during the study,
she will be given TS prophylaxis and remain in the
study. If she was previously randomized to daily TS, she
will continue taking daily TS. If she was previously ran-
domized to take weekly CQ, she will discontinue weekly
CQ. If she was previously randomized to no prophylaxis,
she will begin taking daily TS. Pregnancy outcome infor-
mation will be recorded on a pregnancy outcome case
report form (CRF). When the participant is no longer
pregnant, she may recommence the treatment to which
she was originally assigned, if this is agreed to by the
participant and the study team.
Table 6 Classification of adverse events
Seriousness A serious adverse event includes any untoward medical occurrence that at any dose:
• Results in death,
• Is life-threatening,
• Requires inpatient hospitalization or prolongation of existing hospitalization
• Results in persistent or significant disability/incapacity, or
• Is a congenital anomaly/birth defect
Important medical events that may not be immediately life-threatening or result in death or hospitalization but may jeopardize
the patient or may require intervention to prevent one of the outcomes listed in the definition above may also be considered
serious
Severity Grade 1 Mild Symptoms causing no or minimal interference with usual social and functional activities
Grade 2 Moderate Symptoms causing greater than minimal interference with usual social and functional
activities
Grade 3 Severe Symptoms causing inability to perform usual social and functional activities
Grade 4 Potentially life-
threatening
Symptoms causing inability to perform basic self-care functions or medical or operative
intervention indicated to prevent permanent impairment, persistent disability
Grade 5 Death
Relationship to
study products
Definitely
related
The adverse event and administration of the study agent are related in time, and a direct association can be
demonstrated
Probably
related
The adverse event and administration of the study agent are reasonably associated in time, and the adverse event
is more likely explained by the study agent than other causes
Possibly
related
The adverse event and administration of the study agent are reasonably related in time, and the adverse event
can be explained equally well by causes other than the study agent
Probably not
related
A potential relationship between the study agent and the adverse event could exist (i.e. the possibility cannot be
excluded), but the adverse event is most likely explained by causes other than the study agent
Not related The adverse event is clearly explained by another cause not related to the study agent
Pending Pending may be used as a temporary relationship assessment only for death and only if data necessary to
determine relationship to the study agent are being collected. The site is required to submit a final assessment
within three business days after reporting the death. If no final assessment is made within three business days
after the date of submission, the event will be assessed as possibly related to the study agent. Any additional
information received at a later time, including an autopsy report, should be submitted as a Follow-up Report
Expectedness Expected Expected refers to the perspective of events previously observed, not on the basis of what might be anticipated
from the pharmacological properties of the study agent
Study drug Expected adverse events
Trimethoprim-
sulfamethoxazole
Rash, urticaria, loss of appetite, nausea, vomiting, agranulocytosis, aplastic anemia, disease of
the hematopoietic system, fulminant hepatic necrosis, severe allergic reaction, Stevens-Johnson
syndrome, and toxic epidermal necrolysis
Chloroquine Headache, malaise, dizziness, blurred vision, difficulty focusing, muscle weakness,
electrocardiogram changes, gastrointestinal upset, mouth ulcers, diarrhea, vomiting,
nonurticarial pruritis, leukopenia, methemoglobinemia, and retinopathy
Unexpected Unexpected refers to events whose nature or severity (intensity) is not consistent with those included in the package
insert/summary.
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Criteria for permanent treatment discontinuation
 Requires chronic treatment with an antimalarial
drug
 Study drug-related toxicity such that reintroduction
or desensitization cannot be considered per WHO
guidelines
 Request by the subject to terminate treatment
 Clinical reasons believed to be life-threatening by
the investigators, such as severe allergic reaction
Criteria for premature study discontinuation
 Request by the subject to withdraw
 Opinion of the investigators is that the study is no
longer in the best interest of the subject
 Volunteer is judged by the site investigator to be at
significant risk of failing to comply with the
provisions of the protocol, so as to cause harm to
self or seriously interfere with the validity of the
study results
 Discontinuation at the discretion of the study team,
ethics committee, or the study sponsor
Final study visit
At the final study visit, the WHO performance score will
be measured and approximately 10–12 mL of blood will
be drawn for CD4 count, HIV viral load, CBC, and ALT
and creatinine concentrations. Participants will discon-
tinue their study treatment assignments and will receive
TS prophylaxis according to Malawi national policy.
Management of their HIV care will be transferred to the
government-sponsored ART clinic.
Definition and assessment of adverse events
Definition of adverse event
An adverse event (AE) is any untoward medical occurrence
in a patient or clinical investigation participant who is ad-
ministered a study product/intervention(s). An AE does
not necessarily have a causal relationship with study treat-
ment. An AE can, therefore, be any unfavorable and unin-
tended sign (including an abnormal laboratory finding),
symptom, or disease temporally associated with the use of a
medicinal (investigational) study product/intervention(s),
whether or not related to the medicinal (investigational)
study product/intervention(s).
An unanticipated problem (UP) is defined as an event
(including onsite and offsite AE reports, injuries, side
effects, breaches of confidentiality, deaths or other
problems) that occurs any time during or after the re-
search study, which, in the opinion of the principal in-
vestigator (PI):
 Involves harm to one or more participants or others,
or places one or more participant or others at
increased risk of harm and
 Is unexpected and
 Is related to the research procedures
The occurrence of an AE may come to the attention of
study personnel during study visits and interviews or by a
study participant presenting for medical care, or upon re-
view by a study monitor. Any medical condition that is
present at the time the participant is enrolled will be con-
sidered a baseline condition, and not reported as an AE.
However, if it deteriorates at any time during the study it
will be recorded as an AE.
AEs will be captured on the appropriate case report
forms. AEs will be recorded in study source docu-
ments, and an assessment of whether they are associ-
ated with the study drug, the ART regimen, an
intercurrent illness or another cause will be made. In-
formation to be collected includes event description,
date of onset, clinician’s assessment of seriousness and
severity, relationship to study product, expectedness
and time of resolution/stabilization of the event. AEs
will be followed to adequate resolution or stabilization.
If the AE has not stabilized or resolved at the end of
Table 7 Antimalarial efficacy flow chart
Days after malaria diagnosis→ 0 1 2 3 7 14 21 28 Unscheduled visit (before d28)
Procedure ↓
Clinical Assessment C C C C C C C C C
Temperature C C C C C C C C C
Questioning about antimalarial drug use C C C C C C C C C
Finger stick blood sample for malaria smear C R R R R R R R C
Finger stick blood sample for filter
paper sample for PCR analysis
R R R R R R R R R
Administration of antimalarial drug
(per Malawi Ministry of Health Protocol)
C C C
C= procedures that are part of clinical care
R= research procedures
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the study period, it will be followed for a maximum of
1 year after study completion.
Seriousness of event
AEs will be assessed by study clinicians to determine the
seriousness of the outcome of the event. The April 1996
International Conference on Harmonization (ICH) guid-
ance, “Good Clinical Practice: Consolidated Guidance,”
(ICH E6) defined a serious adverse event (SAE) as “any
untoward medical occurrence that at any dose:
 Results in death
 Is life-threatening
 Requires inpatient hospitalization or prolongation of
existing hospitalization
 Results in persistent or significant disability/
incapacity, or
 Is a congenital anomaly/birth defect.”
Important medical events that may not be immediately
life-threatening or result in death or hospitalization
but may jeopardize the patient or may require inter-
vention to prevent one of the outcomes listed in the
definition above may also be considered to be serious.
(October 1994 ICH guidance (E2A), “Clinical Safety
Data Management: Definitions and Standards for
Expedited Reporting.”)
Severity of event
AEs will be assessed by the investigator using a
protocol-defined grading system (Table 8) and the
Division of AIDS (DAIDS) Adult Toxicity Tables.
(http://rsc.tech-res.com/safetyandpharmacovigilance/) or lo-
cally derived normal ranges (for creatinine and ALT
concentrations). For events not included in the DAIDS
Adult Toxicity Tables or protocol-defined grading system,
the following guidelines will be used to quantify intensity
for clinical AEs:
Grade 1 mild: symptoms causing no or minimal
interference with usual social and functional activities
Grade 2 moderate: symptoms causing greater than
minimal interference with usual social and functional
activities
Grade 3 Severe: symptoms causing inability to perform
usual social and functional activities
Grade 4 Potentially life-threatening: symptoms causing
inability to perform basic self-care functions or medical
or operative intervention indicated to prevent permanent
impairment, persistent disability
Grade 5 Death
When intensity changes occur more frequently than once
a day, the maximum severity for the event should be listed.
Relationship to study products
AEs will have their relationship to study product
assessed using the following terms:
 Definitely related. The AE and administration of the
study agent are related in time, and a direct
association can be demonstrated
 Probably related. The AE and administration of the
study agent are reasonably associated in time, and
the AE is more likely explained by study agent than
other causes
 Possibly related. The AE and administration of the
study agent are reasonably related in time, and the
AE can be explained equally well by causes other
than the study agent
 Probably not related. A potential relationship
between the study agent and the AE could exist (i.e.,
the possibility cannot be excluded), but the AE
event is most likely explained by causes other than
the study agent
 Not related. The AE is clearly explained by another
cause not related to the study agent
 Pending. Pending may be used as a temporary
relationship assessment only for death and only if data
necessary to determine the relationship to the study
agent are being collected. The site is required to
submit a final assessment within three business days
after reporting the death. If no final assessment is
made within three business days after the date of
submission, the event will be assessed as possibly
related to the study agent. Any additional information
received at a later time, including an autopsy report,
should be submitted as a Follow-up Report
Table 8 Severity of grading and use of normal and abnormal laboratory values
Grade 1 Grade 2 Grade 3 Grade 4
Hemoglobin 8.5–10.0 g/dL 7.5–8.4 g/dL 6.5–7.4 g/dL <6.5 g/dL
Absolute neutrophil count 1000–1300/mm3 750–999/mm3 500–749/mm3 <500/mm3
Platelets 100,000–124,999/mm3 50,000–99,999/mm3 25,000–49,999/mm3 <25,000/mm3
Creatinine 1.1–1.3 × ULN 1.4–1.8 × ULN 1.9–3.4 × ULN ≥3.5 × ULN
Alanine aminotransferase 1.25–2.5 × ULN 2.6–5.0 × ULN 5.1–10.0 × ULN >10.0 × ULN
ULN upper limit of normal
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A suspected adverse drug reaction (SADR) is an AE
that could potentially have a causal relationship to the
study agent (definitely, probably, possibly, probably not
related, or for deaths, pending).
Expectedness (expected versus unexpected)
Expected refers to the perspective of events previously
observed, not on the basis of what might be anticipated
from the pharmacological properties of the study agent
(ICH E2A). Expected AEs related to study drugs are
found in Table 6.
Unexpected refers to events whose nature or severity (in-
tensity) is not consistent with those included in the package
insert/summary (ICH E2A). If an unexpected adverse drug
experience is observed that is definitely or probably related
to TS or CQ, it will be reported to the US FDA using the
MedWatch safety information and adverse reporting sys-
tem via the online system at www.fda.gov/MedWatch/
report.htm. An unexpected adverse drug experience is de-
fined as any adverse drug experience that is not listed in
the current labeling for the drug product. This includes
events that may be symptomatically and pathophysiologic-
ally related to an event listed in the labeling but differ from
the event because of greater severity or specificity. “Unex-
pected,” as used in this definition, refers to an adverse drug
experience that has not been previously observed (i.e., in-
cluded in the labeling) rather than from the perspective of
such experience not being anticipated from the pharmaco-
logical properties of the pharmaceutical product.
Adverse event reporting
Only serious, unexpected, related AEs and all deaths will
be reported in an expedited manner.
Regulatory requirements for reporting to the University
of Malawi, the University of Maryland and the DAIDS
clinical representative will be observed. Reporting proce-
dures will follow ICH 4.11, 5.17 and Clinical Safety Data
Management: Definitions and Standards for Expedited
Reporting.
Protocol deviations
Protocol deviations are events that contradict or omit
protocol instructions. Violations that compromise pa-
tient safety or the integrity of trial data will be recorded
and reported to the sponsor and to the responsible regu-
latory authorities, including ethics committees, as re-
quired by the regulations of each group.
Statistics
Sample size and power calculations
The study will randomize approximately 467 participants
to each of the three study arms during a 36-month en-
rollment period and will follow participants for 32–66
months. We estimate that loss to follow-up will amount
to approximately 15 % of the potential follow-up time,
so that the follow-up time available for analysis will aver-
age about 41.6 months per study participant, for a total
of approximately 1619 person-years of follow-up in each
study arm.
For estimating the power of the study, the statistical
null hypothesis is that the effect of TS prophylaxis in
preventing the first occurrence of a severe event, relative
to no prophylaxis, is at least a 35 % reduction in the haz-
ard rate for first occurrences over the study period (i.e.,
that the hazard ratio, HR, is ≤0.65). Our assumption (al-
ternative hypothesis) for power calculation is that there
is no preventive effect of TS, i.e., that HR = 1. The com-
parison will be based on the upper limit of a two-sided
95 % confidence interval (CI) for the TS effect. An upper
limit of less than 35 % – i.e., a reduction significantly
less than 35 % at the one-sided 2.5 % significance level –
will be considered sufficient evidence for discontinuing
TS prophylaxis in this population.
Assuming that the number of severe events follows a
Poisson distribution, the mean of the distribution for a
participant with average follow-up time (41.6 months)
will be approximately 0.236 events, and the probability
that the participant will experience at least one severe
event will be about 0.210. Assuming that this incidence
rate applies to participants taking TS prophylaxis and
those without prophylaxis (i.e., no effect of TS prophy-
laxis), we then expect for the comparison about 196
study participants in both study arms combined to ex-
perience at least one severe event, which gives us an ex-
pectation of about 85 % power that the upper limit of
the 95 % CI for the effect of TS will be less than 35 %
[20]. The same consideration applies to the comparison
of discontinuation of prophylaxis and CQ prophylaxis.
Analysis
Analysis of the primary endpoint
The primary analysis will compare continuation of TS
and discontinuation of TS. It will consist of a 95 % CI
for the effect of TS, relative to no prophylaxis, in pre-
venting the occurrence of a severe event, based on pro-
portional hazards (Cox) regression modeling. The TS
effect is defined as 1 −HR, where HR is the hazard ratio
from the Cox regression model. The analysis will be
done according to the intention-to-treat principle; that
is, each individual’s data will be analyzed according to
the study arm to which the individual was randomized,
regardless of the treatment and amount of treatment ac-
tually received. Study participants who develop a WHO
clinical stage 3 or 4 illness, experience a sustained de-
cline in their CD4 count below 200 cells/mm3, or who
experience ART failure will be given TS prophylaxis and
will continue to be followed in the study. The analytical
Laurens et al. Trials  (2016) 17:322 Page 12 of 18
method for comparing CQ prophylaxis and no prophy-
laxis (i.e., discontinuation of TS) will be the same as for
comparing continuation and discontinuation of TS.
In addition, one or more protocol analyses may be
done if there is substantial lack of adherence or ad-
ministration of a treatment other than the one to
which an individual was randomized. This consider-
ation is particularly important since we will be per-
forming noninferiority analysis of discontinuation of
TS prophylaxis.
Secondary analyses will compare TS prophylaxis to no
prophylaxis, and CQ prophylaxis to no prophylaxis, with
respect to the total number of severe events experienced
(i.e., including multiple events in individual study partici-
pants), using Poisson regression modeling. TS and CQ
prophylaxis will also be compared to each other with re-
spect to the first occurrence and all occurrences of severe
events. We do not plan to adjust p values or CIs for mul-
tiple comparisons.
Analysis of loss of viral suppression
Besides severe events, we are interested in assessing the
value of TS and CQ prophylaxis in preventing loss of viral
suppression. As for the first occurrence of a severe event,
separate comparisons of (1) TS continuation and discon-
tinuation, (2) TS continuation and CQ prophylaxis, and
(3) CQ prophylaxis and TS discontinuation will be done
using Cox regression modeling to estimate two-sided 95 %
CIs for treatment effects, expressed as HRs. Since severe
events are expected to occur mainly in participants who
do not maintain their viral suppression (i.e., who develop
a detectable viral load), we define minimally acceptable
prophylaxis, as for the occurrence of a severe event, as at
least a 35 % effect in preventing loss of viral suppression.
Then the same numbers of losses of viral suppression are
needed for 80 % power to obtain a CI for effect of prophy-
laxis with upper bound less than 35 %, assuming there is
no effect, as for the first occurrence of a severe event. We
expect the probability of maintaining viral suppression
to be approximately 75 % for participants taking TS
prophylaxis who have the average amount of follow-
up (49 months) [21]. Then about 75 participants in
each of the study arms will be expected to lose their
viral suppression during the study. The power to
obtain an upper confidence limit less than 35 % for
effect of prophylaxis is then about 75 % for each of
the comparisons.
Intention-to-treat analysis will be used for all primary
comparisons. This analysis will include all participants
who were randomized, regardless of attendance at follow-
up visits and the duration of study drug administration.
For participants who are no longer being actively followed
at the end of the study, every effort will be made to obtain
their vital status. Per-protocol analysis will be performed
as a secondary analysis for those who complied with
follow-up visits at least every 8 weeks and for study and
ART medication. Analyses will be done in which data on
study volunteers who switch from one study intervention
to another are censored at the time that they develop an
indication for TS prophylaxis, regardless of treatment
assignment.
Data safety and monitoring
In addition to the regular safety monitoring conducted
by the investigators, this trial will be reviewed at least
annually by the US National Institutes of Health (NIH)
NIAID Data and Safety Monitoring Board (DSMB). An
independent biostatistician and/or database management
group will prepare the DSMB report for the scheduled
DSMB meetings. Follow-up intervals of reporting will be
at the discretion of the DSMB based on trends in the
data, but these are planned to occur approximately every
6 months for safety and once per year for efficacy. The
NIH NIAID DSMB can meet more frequently as needed.
The DSMB will be independent from the investigators
and will have full unblinded access to all accumulating
data. The biostatistician and/or database management
group will prepare reports that include:
 Study accrual by month and by study site
 Eligibility violations
 Baseline characteristics
 Protocol adherence report
 Data completeness report
 Periodic summary adverse event report
 Primary and secondary endpoint summaries, overall
and for key subgroups
The initial DSMB review is planned specifically to assess
safety data to assure that there are not dramatic differences
in survival between treatment groups, and to determine the
appropriate frequency of DSMB reporting. If the trial ex-
ecutive committee or DAIDS Clinical Representative has
efficacy or safety concerns, an unscheduled DSMB review
will be requested.
Site monitors under contract to the National Institute of
Allergy and Infectious Diseases (NIAID) DAIDS will visit
participating clinical research sites to review individual sub-
jects’ records, including consent forms, CRFs, supporting
data, laboratory specimen records, and medical records
(physicians’ progress notes, nurses’ notes, individuals’ hos-
pital charts), in order to ensure protection of study subjects,
compliance with the protocol, and accuracy and complete-
ness of records. The monitors also will inspect sites’ regula-
tory files to ensure that regulatory requirements are being
followed and sites’ pharmacies to review product storage
and management.
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The DSMB will review safety and enrollment data ap-
proximately every 6 months after the first study participant
is enrolled and at other intervals if deemed necessary by
the sponsor or study investigators, with input from the
DSMB. Datasets for these analyses will be created in a joint
effort between the data management team and the inde-
pendent statistician. The major purpose of these analyses
will be to review study progress and safety data. Safety out-
come measures to be monitored include SAEs that are
deemed probably or definitely associated with the study in-
terventions and the total number of SAEs in each treatment
group. The number of primary endpoint events (deaths,
WHO stage 3 and 4 events) as well as the number of AEs
of grade 3 or more and the rates of discontinuation of TS
or CQ prophylaxis, and of loss of virologic control will be
included in the safety review. Based on their assessment of
study enrollment, the safety and tolerability of the prophy-
laxis, and any new research evidence from similar clinical
trials, the DSMB will make a recommendation that the
study either continue with no modification; continue with
modification (including the possibility of terminating one of
the prophylaxis arms); or be discontinued, either perman-
ently or temporarily pending further review.
Ethical considerations
Human subjects’ protections
The investigator will ensure that this study is conducted
in full conformity with the principles set forth in The
Belmont Report: Ethical Principles and Guidelines for
the Protection of Human Subjects of Research of the US
National Commission for the Protection of Human Sub-
jects of Biomedical and Behavioral Research (18 April
1979) and codified in 45 CFR Part 46 and/or ICH E6; 62
Federal Regulations 25691 (1997). Key study personnel
will maintain certification in human subjects protection
and good clinical practice (GCP).
Ethical review
This protocol, the informed consent document and any
subsequent modifications were reviewed and approved by
the Institutional Review Board or Ethics Committee re-
sponsible for oversight of the study, including the College
of Medicine of the University of Malawi and the University
of Maryland. The University of Malawi College of Medicine
Research Ethics Committee (COMREC) will be considered
to be the local IRB and the University of Maryland IRB will
be considered to be a remote IRB (Michigan State Univer-
sity IRB will defer to University of Maryland IRB) for the
purpose of reporting SAEs [22].
Informed consent
Informed consent is a process that is initiated prior to
the individual’s agreeing to participate in the study and
continuing throughout the individual’s study participa-
tion. Extensive discussion of risks and possible benefits
of this therapy will be provided to the subjects and their
families. Consent forms describing in detail the study in-
terventions/products, study procedures, and risks are
given to the subject and written documentation of in-
formed consent is required prior to starting interven-
tion/administering study product. Consent forms will be
IRB-approved and the subject will be asked to read and
review the document, or else verbally explained to the
subject (verified by a witness). Upon reviewing the docu-
ment, the investigator will explain the research study to
the subject and answer any questions that may arise.
The subjects will sign the informed consent document
prior to any procedures being carried out specifically for
the study. The subjects should have the opportunity to
discuss the study with their surrogates and adequately
consider it prior to agreeing to participate. Subjects may
withdraw consent at any time throughout the course of
the trial. A copy of the informed consent document will
be given to subjects for their records. The rights and
welfare of study subjects will be protected by emphasiz-
ing to them that the quality of their medical care will
not be adversely affected if they decline to participate in
this study. During the informed consent process, partici-
pants agree that if their individual data are presented in
manuscript form or in scientific meetings, they will be
identified by study number and not by name to protect
participant confidentiality.
Potential risks
Potential risks anticipated for the study participants in-
clude study drug-specific effects, risks associated with
blood drawing, potential increased risk of opportunistic
infections, and potential loss of confidentiality regarding
HIV status.
The drugs used in this trial are not investigational new
drugs. They have both been widely used for many decades
throughout the world and particularly in Africa, at the
doses and for the indications they will be used for in this
trial. Their safety profiles are favorable and well known.
However, as with any drug, risks do exist. Though CQ is
considered safe, adverse reactions to this drug may occur.
Commonly reported symptoms include headache, malaise,
dizziness, blurred vision, difficulty focusing, muscle weak-
ness and mild gastrointestinal upset. Nonurticarial pruri-
tis, without rash, is a problem that is more common
among dark-skinned patients. The symptom usually be-
gins within the first day after the initial dose and may last
for up to 7 days. Severe adverse reactions are extremely
rare [23]. CQ is well known to be safe in pregnancy and is
routinely recommended for both malaria treatment and
malaria prophylaxis in pregnant women.
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Common adverse reactions associated with TS use in-
clude rash, urticaria, loss of appetite, nausea and vomiting.
Rare, serious side effects include agranulocytosis, aplastic
anemia, disease of the hematopoietic system, fulminant
hepatic necrosis, severe allergic reaction, Stevens-Johnson
syndrome, and toxic epidermal necrolysis [24]. TS is con-
sidered to be relatively contraindicated in pregnancy (class
C) because of theoretical risks of neural tube defects in
the first trimester and kernicterus in the third trimester.
However, both the WHO [13] and the Malawi Ministry of
Health presently recommend TS prophylaxis for people
living with HIV (PLHIV), including in pregnant women.
Finger pricks and venipuncture are associated with
small risks of bleeding, hematoma and infection. To
minimize this risk, the skin will be cleaned with alcohol
prior to puncture and sterile, unused needles and lancets
will always be used and pressure will be held at the punc-
ture site after removal of the needle or lancet. Although
the quantity of blood drawn would not lead to any ill ef-
fects on the participants’ health, some adults feel faint fol-
lowing phlebotomy. The risks will be minimized by having
trained technicians perform the procedure. Clinicians will
be available to evaluate the participant if there is any unto-
ward effect.
Study subjects who are assigned to the CQ or no treat-
ment arms may be at increased risk for opportunistic in-
fections. However, the fact that immune reconstitution
will have already taken place in these individuals reduces
this theoretical risk substantially [25, 26]. Additionally,
the risk of TS prophylaxis-associated adverse reactions
must be weighed against the unknown, potential benefit
of TS prophylaxis in this population. The potential risk
of increased infection in those not taking TS will be
minimized by close follow-up and monitoring, which
will lead to prompt diagnosis and treatment of bacterial
infections and malaria should they occur.
As with any study involving HIV-positive individuals,
there is a risk of loss of confidentiality regarding HIV
status. Our study team is well known in the community
for conducting studies of malaria, so clinic attendance
and home visits will not necessarily identify participants’
HIV status. Efforts to reduce this risk will be a priority.
Patients’ medical records will be kept in a locked cabinet
in a locked room. The study documentation, data and all
other information generated will be kept in strict confi-
dence. No personal information will be released to any
unauthorized third party without the consent of the par-
ticipant. Participant specimens and case report forms
(CRFs) will be identified by a study code with the master
key will be kept in a separate, locked cabinet.
Benefits
Study participants will receive a higher standard of med-
ical care than is typically available in Malawi. Close
follow-up is likely to identify HIV-related illnesses
sooner than they would otherwise be detected. We will
pursue complete diagnostic evaluation of illness episodes
and maintain a supply of medication to treat common
diseases.
Alternatives to study participation
Participants may withdraw from the study at any time.
Those who withdraw will be referred for treatment at
the local government-sponsored ART clinic. The reason
for withdrawal will be recorded. Whenever possible,
endpoint data will be collected for participants who
withdraw or are withdrawn from the study in order to
include their data in the intention-to-treat analysis.
Sample sharing and storage
Samples collected will be maintained after the study is
complete if the participant has agreed to this during the
informed consent process and indicated permission on
the written document. Any analysis of these specimens
that is outside the scope of the objectives of this proto-
col will be submitted for prior review and approval by
the appropriate IRBs. Parasites, viruses and their genetic
material may be unlinked for further analysis, without
any identifying clinical information. Should a participant
change their mind at any time and revoke authorization
for specimen storage with identifying information, their
remaining samples will be unlinked from identifying in-
formation prior to analysis or else destroyed at the par-
ticipant’s request.
Data
Data collection and entry
The PI is responsible for ensuring the accuracy, com-
pleteness, legibility and timeliness of the data reported.
All source documents will be completed in a neat, le-
gible manner to ensure accurate interpretation of data.
Records will be kept in locked files.
Copies of the electronic CRF (eCRF) will be provided
for use as source documents and maintained for record-
ing data for each subject enrolled in the study. Data re-
ported in the eCRF derived from source documents
should be consistent with the source documents, or the
discrepancies should be explained.
All source documents and laboratory reports will be
reviewed by the study team and data entry staff to ensure
that they are accurate and complete. AEs must be graded,
assessed for severity and causality, and reviewed by the PI,
an investigator, or a clinical coordinator. Data collection is
the responsibility of the clinical trial staff at the Blantyre
Malaria Project Research Clinic and at Dignitas Inter-
national under the supervision of a clinical coordinator and
the investigators. During the study, the investigator must
maintain complete and accurate documentation for the
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study. The Statistical and Data Coordinating Center for this
study will be responsible for the data management, quality
review, analysis, and reporting of the study data.
Appropriate medical and research records will be main-
tained for this trial, in compliance with ICH E6 and any
applicable DAIDS policies. Study investigators and the
clinical coordinator will have access to all study records.
Study nurses and clinicians will have access to the labora-
tory source documents and CRFs of participants who are
being actively enrolled and followed. Laboratory staff will
have access to laboratory source documents. Data entry
clerks and the data manager will have access to the CRFs.
Authorized representatives of DAIDS will be permitted to
examine (and when required by applicable law, to copy)
clinical records for the purposes of quality assurance re-
views, audits and evaluation of study safety and progress.
The final trial dataset will be available to study investiga-
tors at the end of the study.
Quality control and quality assurance
The site developed a protocol-specific quality management
plan in conjunction with the University of Maryland Center
for Vaccine Development Office of Regulatory Affairs and
Quality Management. This plan will be in place for quality
management, including how the data will be evaluated for
compliance with protocol, which documents will be
reviewed and methods of training staff. The study will be
conducted at the Blantyre Malaria Project Research Clinic
at Ndirande Health Centre and at the Tisungane Clinic at
Zomba Central Hospital in Zomba. Recruitment activities
will occur at outpatient ART clinics at these sites. Labora-
tory testing will also be performed at certified laboratories
for testing according to the protocol analyte list.
Site monitoring will be conducted by a DAIDS con-
tractor to assure protocol compliance, ethical standards,
regulatory compliance and data quality.
Following written standard operating procedures (SOPs),
the monitors will verify that the clinical trial is being con-
ducted and data are generated, documented (recorded),
and reported in compliance with the protocol, GCP and
the applicable regulatory requirements. Reports will be sub-
mitted to DAIDS on monitoring activities. The investigative
team will provide direct access to source data/documents
and reports for the purpose of monitoring and auditing by
the sponsor and inspection by local and regulatory author-
ities. The data manager will implement quality control pro-
cedures beginning with the data entry system and generate
data quality control checks that will be run on the database.
Any missing data or data anomalies will be communicated
to the site for clarification and resolution.
Monitoring
Study monitoring will be conducted to ensure participant
safety compliance of study conduct with 45 CFR 46, GCP,
ICH and DAIDS guidelines. A separate monitoring plan
will be developed by DAIDS and implemented by the
DAIDS Clinical Site and Study Monitoring Contractor.
The site monitors will visit participating clinical re-
search sites to review individual subject records, includ-
ing consent forms, CRFs, supporting data, laboratory
specimen records, and medical records (physicians’ pro-
gress notes, nurses’ notes, individuals’ hospital charts),
and to ensure protection of study subjects, compliance
with the protocol and accuracy and completeness of re-
cords. The monitors also will inspect sites’ regulatory
files to ensure that regulatory requirements are being
followed and sites’ pharmacies to review product storage
and management.
Plans for dissemination of results
The PI and co-investigators regularly participate in local
and national meetings in Malawi to discuss malaria and
HIV issues as well as local research meetings at the Uni-
versity of Malawi College of Medicine. The findings will
be presented at the annual College of Medicine Research
Dissemination Day and at other appropriate conference
venues. Study results will also be shared expeditiously
with Malawian HIV and malaria control officials and the
Malawi Ministry of Health and its local representatives.
Results will be submitted for publication to local and
international journals in accordance with authorship
guidelines established by the International Committee of
Medical Journal Editors. The study protocol will be pro-
vided in publication supplementary materials.
Discussion
Clinical trial coordination
Daily study activities are managed onsite by a study
physician, with visits twice weekly by a senior study
physician with HIV management expertise. Challenging
clinical cases are scheduled on days when senior physi-
cians are onsite. The local study teams participate in
weekly teleconferences with international investigators
to discuss study progress, challenges and planning. SAEs
are identified by the study team and reported to senior
physicians and international investigators via email and/
or phone to refine diagnostics and management as
needed. International investigators make regular visits to
the study sites approximately every other month to re-
view progress and assist in study coordination.
Trial status
The study began recruitment activities at the Ndirande
site in November 2012. By mid-February 2015, 900 par-
ticipants had been recruited. The DSMB evaluated study
progress as planned, starting in 2013, and determined
that the study was being conducted well and should
continue.
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During the first year of follow-up in 2013, study inves-
tigators noted several pregnancies in study participants
who had agreed to practice contraception during the in-
formed consent process. As a result, the study team im-
plemented checks at scheduled follow-up visits to
ensure that participants were able to access family plan-
ning methods in the community, and to facilitate referral
to family planning clinics for contraception. As a result,
the incidence of pregnancy in the study population has
decreased.
Initially, the trial was designed to recruit 900 partici-
pants, with the rationale that the primary endpoint event
rate in the entire participant population would be 15 per
100 person-years. As no prospective data were available at
the time, this assumption was based on a post-hoc analysis
of retrospective data from a similar population. As the
study accrued participants, the overall event rate was
reviewed regularly due to this uncertainty, and the event
rate observed in the study population was 6.8 per 100
person-years as of an interim database lock of July 2014.
Sample size determination was revisited at that time, and
it was determined that adding approximately 500–600
participants and 2 years of follow-up should provide the
expected 350 primary endpoint events needed for primary
endpoint analysis. The sponsor agreed to extend and ex-
pand the study in early 2015, and a second site, Zomba,
was added for recruitment and follow-up in mid-2015. A
Standardized Protocol Items: Recommendations for Inter-
ventional Trials (SPIRIT) checklist is provided in the sup-
plementary materials as Additional file 1.
Additional file
Additional file 1: Completed SPIRIT checklist. Standardized Protocol
Items: Recommendations for Interventional Trials checklist. (PDF 90 kb)
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